Clinical trials: Immunoglobulin Therapy
Unresectable Locally Recurrent Rectal Cancer
SBRT + PD-1 Antibody in Unresectable Locally Recurrent Rectal Cancer（SPARKLE）
This is a prospective study to delve into the therapeutic benefits of combining stereotactic body radiation therapy (SBRT) with PD-1 monoclonal antibody treatment for patients with unresectable locally recurrent rectal cancer…
- Trial name
- NCT06767007
- Testing
- Stereotactic Body Radiation Therapy (SBRT), PD1, Chemotherapy
- Where
- China
- Volunteers
- 31 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Soft Tissue Sarcoma
APX005M and Doxorubicin in Advanced Sarcoma
This phase II clinical trial will evaluate the safety and efficacy of adding APX005M (a CD40 agonistic monoclonal antibody) to doxorubicin for the treatment of patients with advanced soft tissue sarcoma.
- Trial name
- NCT03719430
- Testing
- Doxorubicin, APX005M
- Where
- 3 sites in United States
- Volunteers
- 27 people
- Sponsor
- Alexander Z. Wei, MD
Advanced Solid Tumor
A Study of MRG002 in the Treatment of Patients With HER2-positive Advanced Solid Tumors
The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG002 in patients with HER2-positive advanced solid tumors.
- Trial name
- NCT04941339
- Testing
- MRG002
- Where
- China
- Volunteers
- 74 people
- Sponsor
- Shanghai Miracogen Inc.
Hepatitis C, Liver Transplantation
Comparing Efficacy and Safety of Tacrolimus With Steroids or Monoclonal Anti-IL2R Antibody in Hepatitis C Virus (HCV) Positive Liver Transplant Patients
This is an exploratory study to evaluate the impact of eliminating steroid administration upon viral HCV load at 12 months measured by quantitative serum HCV-RNA determination in patients transplanted for HCV cirrhosis.
- Trial name
- CHASE (NCT00295607)
- Testing
- Tacrolimus, steroids, monoclonal anti-IL2R antibody
- Where
- 17 sites in Czechia, France and 6 more
- Volunteers
- 138 people
- Sponsor
- Astellas Pharma Inc
Hepatitis B, Liver Transplantation
HepeX-B in Post Hepatic Allografts for Treatment of End Stage Liver Disease Due to Hepatitis B Infection
The purpose of this study is to compare the use of HepeX-B versus HBIg, two anti-viral drugs, in patients who have received liver transplants due to liver failure caused by Hepatitis B infection.
- Trial name
- NCT00228592
- Testing
- HepeX-B, Hepatitis B Immune Globulin (HBIg)
- Where
- 20 sites in United States, France and 5 more
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Diarrhea Predominant Irritable Bowel Syndrome, Small Intestinal Bacterial Overgrowth
Use of SBI in IBS Subjects Following a Successful Treatment of Small Intestinal Bacterial Overgrowth
The primary objective of this study is to determine whether giving SBI as a medical food starting with maintenance of health in the management of chronic loose and frequent stools in IBS-D subjects with SIBO after successful…
- Trial name
- NCT02251483
- Testing
- Serum-derived bovine immunoglobulin protein isolate (SBI)
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Cedars-Sinai Medical Center
NK T-Cell Lymphoma
Phaes Ⅱ Study of Golidocitinib-Pegaspargase-PD-1 Antibody First-Line for Advanced ENKTL
Extranodal natural killer/T-cell lymphoma (ENKTL) is an aggressive non-Hodgkin lymphoma with poor prognosis in advanced stages, with a 5-year overall survival (OS) rate of less than 30% despite asparaginase-based regimens.
- Trial name
- NCT07457177
- Testing
- Golidocitinib + Pegaspargase + Anti-PD-1 mAb
- Volunteers
- 40 people
- Sponsor
- LIANG WANG
Rheumatoid Arthritis, Juvenile Idiopathic Arthritis
Anti-Biopharmaceutical Immunization: Prediction and Analysis of Clinical Relevance to Minimize the Risk of Immunization in Rheumatoid Arthritis Patients or Juvenile Idiopathic Arthritis Patients
One of the main potential causes of these failures of BP therapy response is the development of Anti-drug Anti-body (ADAb) in some patients.
- Trial name
- ABI-RA (NCT02116504)
- Testing
- Sampling of blood
- Where
- France
- Volunteers
- 156 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Mantle Cell Lymphoma
Chemotherapy Combined With Targeted Therapy as First-line Treatment for Mantle Cell Lymphoma Based on MRD and PET-CT Assessment
This is a single-arm, multi-center, prospective, phase II study. The primary objective is to assess the efficacy and safety of bendamustine/orelabrutinib combined with an anti-CD20 monoclonal antibody in treatment-naïve patients…
- Trial name
- ADAPT-MCL (NCT07206264)
- Testing
- Bendamustine + anti-CD20 monoclonal antibody/orelabrutinib + anti-CD20 monoclonal antibody
- Where
- 5 sites in China
- Volunteers
- 45 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Solid Tumor
Radiotherapy Combined With Irinotecan and Apatinib Followed by PD-1 Antibody and Apatinib for Advanced Solid Tumors
An exploratory study to evaluate for the treatment of advanced solid tumors that failed standard treatments.
- Trial name
- NCT04569916
- Testing
- radiotherapy, irinotecan liposome, apatinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Warm Antibody Autoimmune Hemolytic Anemia
HMPL-523 (Sovleplenib) in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
Phase II Study: To evaluate the safety and preliminary efficacy of HMPL-523 in adult patients with wAIHA. Phase III Study(Part A): Confirmation of Efficacy safety and of HMPL-523 in adult patients with wAIHA.
- Trial name
- wAIHA (NCT05535933)
- Testing
- HMPL-523(300mg PO QD)
- Where
- 39 sites in China
- Volunteers
- 111 people
- Sponsor
- Hutchmed
Lymphoma, Large-Cell, Anaplastic, Lymphoma, Non-Hodgkin
A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma
This is a single-arm, open-label, multicenter, clinical trial to evaluate the efficacy and safety of brentuximab vedotin (SGN-35) as a single agent in patients with relapsed or refractory ALCL.
- Trial name
- NCT00866047
- Testing
- brentuximab vedotin
- Where
- 22 sites in United States, Belgium and 3 more
- Volunteers
- 58 people
- Sponsor
- Seagen Inc.
Uveitis
ANTI-TAC THERAPY FOR UVEITIS
Uveitis refers to intraocular inflammatory diseases that are an important cause of visual loss. Standard systemic immunosuppressive medications for uveitis can cause significant adverse effects.
- Trial name
- NCT00001526
- Testing
- Daclizumab (Zenapax)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Eye Institute (NEI)
Carcinoma, Non-Small-Cell Lung, Neoplasms
A Dose-Finding Study of the Second Mitochondrial Activator of Caspases (SMAC) Mimetic Debio 1143 When Given in Combination With Avelumab to Participants With Advanced Solid Malignancies and to Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Platinum-Based Therapy
The study is primarily designed to assess the safety and tolerability of escalating oral doses of Debio 1143 and preliminary anti-tumour activity when combined with the standard dose of avelumab in participants with advanced…
- Trial name
- NCT03270176
- Testing
- Debio 1143, Avelumab
- Where
- 9 sites in Canada, Poland and 1 more
- Volunteers
- 54 people
- Sponsor
- Debiopharm International SA
Multiple Myeloma
2015-09: a Phase II Randomized, Open-label Study of Anti-signaling Lymphocytic Activation Molecule Monoclonal Antibody During Maintenance Therapy
This study will compare the effectiveness and safety of maintenance therapy with continuous bortezomib, lenalidomide, and dexamethasone (VRD) compared to maintenance therapy that alternates VRD with Elotuzumab, lenalidomide, and…
- Trial name
- NCT03000634
- Testing
- Elotuzumab, Bortezomib, Lenalidomide
- Sponsor
- University of Arkansas
Gastric Adenocarcinoma
A Study of Disitamab Vedotin, Tunlametinib, and PD-1 Antibody for Advanced Gastric Cancer
The goal of this clinical trial is to learn if the combination of disitamab vedotin, tunlametinib, and a PD-1 antibody works to treat HER2-overexpressing advanced gastric cancer in patients who have already received at least two…
- Trial name
- DTP-HER2 (NCT07507526)
- Testing
- Tunlametinib+PD-1 mAb
- Where
- China
- Volunteers
- 76 people
- Sponsor
- Sun Yat-sen University
Leukemia
Monoclonal Antibody Therapy and Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia in Remission
RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver tumor-killing substances to them, without harming normal cells.
- Trial name
- NCT00002609
- Testing
- lintuzumab, cytarabine, idarubicin
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Anemia, Hemolytic, Autoimmune
Prednisolone +/- Addition of Anti-CD20 Antibody, Rituximab, in Patients With Immune Hemolytic Anemia
The conventional treatment in warm-antibody dependent autoimmune haemolytic anaemia (AIHA) is high-dose glucocorticoid, but in more than half of the patients, haemolytic activity will recur after end of treatment or during the…
- Trial name
- NCT01134432
- Testing
- prednisolone + mabthera, Prednisolone
- Where
- 11 sites in Denmark
- Volunteers
- 65 people
- Sponsor
- Copenhagen University Hospital at Herlev
Myeloma
Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM)
The goal of this clinical research study is to find the highest tolerable dose of Siltuximab that can be given in combination with Velcade (bortezomib), Revlimid (lenalidomide), and dexamethasone to patients with MM.
- Trial name
- NCT01531998
- Testing
- Lenalidomide, Bortezomib, Siltuximab
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- M.D. Anderson Cancer Center
Gastric Cancer, AFP
PD-1 Antibody + Apatinib Mesylate in 2+ Line Serum AFP-elevated Gastric Adenocarcinoma
The purpose of this study is to evaluate the efficacy and safety of PD-1 antibody combined with apatinib mesylate in patients with unresectable, local advanced recurrent or metastatic serum AFP-elevated gastric adenocarcinoma…
- Trial name
- NCT04006821
- Testing
- PD-1 antibody, Apatinib mesylate
- Where
- China
- Volunteers
- 30 people
- Sponsor
- China Medical University, China
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.